News GSK and J&J lead in vaccines research – but pricing still an... GlaxoSmithKline and Johnson & Johnson are leading R&D investment in vaccines, and the field is producing the first ever vaccines for conditions such as Ebola and a range of deadly b
News J&J to work with Orthocell on new regenerative stem cell the... Multi-centre trial of Ortho-ATI technology planned for early 2017.
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News No US Remicade biosimilar until at least October Pfizer must wait until 180 day period ends, court fight ongoing.
Views & Analysis A history of Johnson & Johnson Set up by three brothers back in 1886, Johnson & Johnson continues to keep evolving
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.